• 5 min read
• Published on 7 January 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
Every now and then, a headline cuts through the usual market noise and forces even a jaded old cynic like me to sit up and pay attention. Regeneron announcing a 100% complete response rate in a lymphoma trial was one of those moments. One hundred percent. In medicine, and especially in oncology, you just don’t see that number. It sounds more like a dictator’s election results than a clinical trial outcome. But here we are.
This isn’t just another small step forward. To me, it feels like a different game entirely. It signals that the field of immuno-oncology, long touted as the future, might finally be delivering on its rather grand promises. For investors, this kind of news is both thrilling and terrifying. Thrilling because of the sheer potential, and terrifying because biotech is a notorious graveyard for capital.
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
So, what is this miracle cure? At its heart is something called a bispecific antibody. Forget the jargon. Think of it like a highly specialised molecular matchmaker. Traditional chemotherapy is a bit of a brute, a sledgehammer that smashes cancer cells but often takes a lot of healthy ones with them. It’s effective, but messy. Immuno-oncology is far more elegant.
These new therapies don’t attack the cancer directly. Instead, they grab one of your body’s own immune cells by the hand, drag it over to a cancer cell, and say, "Right, you see this chap? He's not supposed to be here. Do your job". By physically connecting the hunter to the hunted, it unleashes the full, targeted power of your immune system. Regeneron’s result suggests this matchmaking service is exceptionally good at its job. The implications are enormous, potentially shifting cancer treatment from a war of attrition to a precision strike.
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
Of course, Regeneron isn’t the only player in this sophisticated new game. You have companies like Moderna, famous for its COVID jab, now applying that same mRNA technology to create personalised cancer vaccines. They essentially take a mugshot of a patient’s unique tumour and create a bespoke vaccine to train the immune system to hunt it down. It’s the Savile Row of cancer treatment.
Then there’s Gilead, which is pioneering a different route with CAR T-cell therapy. This involves taking a patient’s own immune cells out of their body, genetically re-engineering them in a lab to be better cancer killers, and then putting them back in. It’s complex, it's expensive, but for some blood cancers, the results have been nothing short of miraculous. The sheer variety of these approaches shows just how much intellectual and financial firepower is being aimed at this problem. It begs the question for anyone with a bit of risk appetite, when it comes to Cancer Therapies: What's Next After 100% Response Rate, where does one even begin?
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
Let's be clear. Investing in individual biotech firms is not for the faint of heart. For every Regeneron, there are a dozen companies whose promising drugs fail in late-stage trials, taking shareholder fortunes with them. A single clinical setback can wipe out a company’s value overnight. It’s a high-stakes game of scientific and regulatory roulette.
This is why, for most people, a thematic approach makes a great deal more sense. Instead of betting the farm on a single company’s miracle cure, you can spread your investment across a basket of the leading innovators. You get exposure to the bispecific antibodies, the mRNA vaccines, and the cellular therapies all at once. It’s a way of participating in the revolution without being entirely dependent on one particular battle turning out right. By diversifying, you smooth out the terrifying volatility of the sector while keeping a stake in what could be one of the most important medical advances of our lifetime.
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
View the full Basket:Cancer Therapies: What's Next After 100% Response Rate
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article